| 1. |
|
|
| 2. |
- Aydogdu, Özgu, 1978, et al.
(författare)
-
Cross-organ sensitization between the prostate and bladder in an experimental rat model of lipopolysaccharide (LPS)-induced chronic pelvic pain syndrome.
- 2021
-
Ingår i: BMC urology. - : Springer Science and Business Media LLC. - 1471-2490. ; 21:1
-
Tidskriftsartikel (refereegranskat)abstract
- The aim of the current study was to investigate the effects of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) on bladder function via prostate-to-bladder cross-sensitization in a rat model of lipopolysaccharide (LPS)-induced prostate inflammation.Male rats were intraprostatically injected with LPS or saline, serving as control. Micturition parameters were examined in a metabolic cage 10 or 14days later. Subsequently, to evaluate bladder function, cystometry was performed. Micturition cycles were induced by saline infusion and cholinergic and purinergic contractile responses were measured by intravenous injection with methacholine and ATP, respectively. Thereafter, the prostate and bladder were excised and assessed histopathologically for possible inflammatory changes.Metabolic cage experiments showed increased urinary frequency in rats with LPS-induced CP/CPPS. Cystometry showed a significant increase in the number of non-voiding contractions, longer voiding time and lower compliance in CP/CPPS animals compared to controls. Induction of CP/CPPS led to significantly reduced cholinergic and purinergic bladder contractile responses. Histopathological analysis demonstrated prostatic inflammation in CP/CPPS animals. There were no significant differences between the groups regarding the extent or the grade of bladder inflammation. Prostate weight was not significantly different between the groups.The present study shows that prostate-to-bladder cross-sensitization can be triggered by an infectious focus in the prostate, giving rise to bladder overactivity and alterations in both afferent and efferent signalling. Future studies are required to fully understand the underlying mechanisms.
|
|
| 3. |
|
|
| 4. |
|
|
| 5. |
|
|
| 6. |
- Aydogdu, Özgu, 1978, et al.
(författare)
-
Prostate-to-bladder cross-sensitization in a model of zymosan-induced chronic pelvic pain syndrome in rats.
- 2021
-
Ingår i: The Prostate. - : Wiley. - 1097-0045 .- 0270-4137. ; 81:4, s. 252-260
-
Tidskriftsartikel (refereegranskat)abstract
- The aim of the present study was to investigate the effects of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) on bladder function and pathophysiology.To create a model for CPPS, rats were intraprostatically injected with zymosan or saline, serving as control. Metabolic cage experiments were performed 7, 14, or 21 days after zymosan injection and after 14 days in the control group. Thereafter, cystometry was performed in which simulated micturition cycles were induced by saline infusion and contractile responses to the cholinergic agonist methacholine and the purinergic agonist ATP were measured. Following cystometry, the prostate and urinary bladder were excised and assessed histopathologically for possible inflammatory changes.Metabolic cage data revealed a significantly increased urinary frequency in zymosan treated rats. Likewise, the volume per micturition was significantly lower in all CPPS groups compared to controls. Cystometry showed a significant increase in the number of nonvoiding contractions, longer voiding time, and a trend towards lower compliance in CPPS rats compared to controls. Induction of CPPS led to significantly reduced cholinergic and purinergic contractile responses. Histopathological analysis demonstrated prostatic inflammation in all CPPS groups, in particular in later stage groups. Both the extent and grade of bladder inflammation were significantly higher in CPPS groups compared to controls.The current findings demonstrate a potential prostate-to-bladder cross-sensitization leading to symptoms of bladder overactivity and signs of bladder inflammation. Future clinical studies are required to verify the outcomes of the current study and enable advancement of patient care.
|
|
| 7. |
- Aydogdu, Özgu, 1978, et al.
(författare)
-
Teachers' Perspectives on Improving Online Seminars in Pharmacology: A Quantitative and Qualitative Study on Lessons Learned During the COVID-19 Pandemic
- 2022
-
Ingår i: Medical Science Educator. - : Springer Science and Business Media LLC. - 2156-8650. ; 32, s. 1131-1142
-
Tidskriftsartikel (refereegranskat)abstract
- The aim of this study is to evaluate teachers' perceptions of online seminars during COVID-19 pandemic to improve future courses in pharmacology. The study was performed as a questionnaire survey. A questionnaire that included 11 questions was used. A total of 14 online seminar teachers, of which 9 were senior teachers and 5 were PhD students, filled out the questionnaire. PhD students' and senior teachers' answers to questions 1-5 were compared statistically. The results of questions 6-10 were analysed qualitatively through thematic content analysis. There were no significant differences between senior teachers and PhD students in regard to the scores given to questions 1-5 in the questionnaire. Most (65%) teachers scored the online seminars lower than in person seminars. Interaction, communication, and group dynamics were mostly perceived to be less effective at online seminars compared to in person seminars. The main advantages of online seminars were time saving and flexibility. The main disadvantages of online seminars were reduced student interest, risk of monologue discussion and poorer communication without body language. Most teachers experienced minor technical problems with internet connection and sound quality. The teachers mentioned that better group dynamics, smaller groups, better chat functionality and clearer guidelines could help to improve online seminars. As an alternative to online seminars, blended-learning could be used. This way, one could appreciate both the richness of interactions in a face-to-face environment as well as the flexibility and convenience of online learning. Further studies comparing blended-learning and online teaching at seminars are needed to investigate this issue.
|
|
| 8. |
|
|
| 9. |
- Aydogdu, Özgu, 1978, et al.
(författare)
-
Treatment with the soluble guanylate cyclase activator BAY 60-2770 normalizes bladder function in an in vivo rat model of chronic prostatitis.
- 2022
-
Ingår i: European journal of pharmacology. - : Elsevier BV. - 1879-0712 .- 0014-2999. ; 927
-
Tidskriftsartikel (refereegranskat)abstract
- Chronic pelvic pain syndrome (CPPS) is a common and bothersome condition for which no pharmacological treatment options with acceptable efficacy exist. The aim of this study was to investigate the effects of the soluble guanylate cyclase (sGC) activator BAY 60-2770 and the COX-2 inhibitor celecoxib on bladder function in a rat model of CPPS.Forty-eight male Sprague-Dawley rats were intraprostatically injected with either saline, serving as control, or zymosan, to induce prostatitis. On days 8-20, the rats were treated with either dimethylsulphoxide (DMSO; vehicle), celecoxib, BAY 60-2770 or a combination of celecoxib and BAY 60-2770. Thereafter, micturition parameters were assessed in a metabolic cage and urine samples were collected. The following day, cystometry was performed. Subsequently, the urinary bladder and prostate were removed and examined histopathologically.Induction of prostatitis led to a significant increase of micturition frequency and corresponding decrease of volume per micturition. These alterations were ameliorated by celecoxib, and completely normalized by BAY 60-2770. Induction of prostatitis led to a significantly increased number of non-voiding contractions, decreased bladder compliance and increased voiding time. These parameters were normalized by treatment with BAY 60-2770, either alone or in combination with celecoxib. The immunohistochemical analysis showed signs of prostate inflammation, but not bladder inflammation.Induction of prostatitis led to significant impairment in bladder function. These alterations could be prevented by BAY 60-2770, alone or in combination with celecoxib. This is the first study to show that sGC activators could be a promising option for the treatment of CPPS.
|
|
| 10. |
- Aydogdu, Özgu, 1978, et al.
(författare)
-
Treatment with the soluble guanylate cyclase activator BAY 60-2770 restores in vitro bladder contractile responses in a rat model of chronic prostatitis
- 2022
-
Ingår i: Continence. - : Elsevier BV. - 2772-9737. ; 4
-
Tidskriftsartikel (refereegranskat)abstract
- Aim: Examine how innate bladder contractility and corresponding receptor expression was affected by chronic prostatitis (CP) and how treatment with the soluble guanylate cyclase (sGC) activator BAY 60-2770 influenced this. Methods: To create a functional model for CP, 24 male Sprague-Dawley rats were intraprostatically injected with either zymosan or saline, serving as control. After a recovery period, the rats were treated with either BAY 60-2770 or dimethyl sulfoxide (DMSO; vehicle) on days 8–20. Urine samples were collected for measurement of ATP. On day 21, the bladder was excised and contractile responses to electrical field stimulation (EFS), methacholine, ATP and nitric oxide (NO) were examined in an in vitro organ bath. Subsequently, the expression of purinergic (P2X1 & P2X3) and muscarinic (M3) receptors as well as sGC was examined immunohistochemically. Results: Induction of CP led to significantly attenuated purinergic bladder contractions, which were normalized by treatment with BAY 60-2770. Induction of CP did not alter the contractile bladder responses to EFS, methacholine or NO. However, treatment with BAY 60-2770 led to significantly increased contractile bladder responses to EFS and MeCh and significantly enhanced relaxatory nitrergic responses. There were no significant differences between the groups regarding purinergic or cholinergic receptor expression, however treatment with BAY 60-2770 led to attenuated expression of sGC in the urothelium. Conclusion: Taken together, these findings indicate that drugs targeting the nitric oxide/cyclic guanosine monophosphate (NO/cGMP) pathway may be a promising option to restore alterations in bladder contractility that arise due to CP.
|
|
